Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 20/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20816299 | 1.00 | GLP1R (0.80) | GLP1R | |
| SCHEMBL29743095 | 0.98 | GLP1R (0.81) | GLP1R | |
| SCHEMBL29362765 | 0.98 | GLP1R (0.83) | GLP1R | |
| SCHEMBL29363146 | 0.98 | GLP1R (0.83) | GLP1R | |
| SCHEMBL31731011 | 0.98 | GLP1R (0.83) | GLP1R | |
| SCHEMBL30721588 | 0.98 | GLP1R (0.83) | GLP1R | |
| SCHEMBL29359146 | 0.98 | GLP1R (0.83) | GLP1R | |
| SCHEMBL29823404 | 0.98 | GLP1R (0.83) | GLP1R | |
| SCHEMBL29942457 | 0.98 | GLP1R (0.83) | GLP1R | |
| SCHEMBL27827907 | 0.98 | GLP1R (0.83) | GLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 690 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4691496-A1 | PHARMACEUTICAL PREPARATION CONTAINING GLP-1 FUSION PROTEIN AND USE THEREOF | Guangzhou Innogen Pharmaceutical Group Co., Ltd. (CN) | 2026-02-11 | — | — | EP | claimed |
| US-12544371-B2 | Methods and compositions for treating acute lung injury and acute respiratory distress syndrome | CALCIMEDICA, INC. (US) | 2026-02-10 | — | — | US | claimed |
| US-20250367218-A1 | METHODS OF TREATING METABOLIC DISORDERS AND COMBINATION PRODUCTS FOR USE IN THE SAME | BATTHYANY CARLOS (UY) | 2025-12-04 | — | — | US | claimed |
| US-12435149-B2 | Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (GIPR) in combination with GLP-1 agonists | AMGEN INC. (US) | 2025-10-07 | — | — | US | claimed |
| EP-3787631-B1 | MODULATORS OF ORPHAN NUCLEAR RECEPTORS FOR NASH AND OTHER METABOLIC DISORDERS | UNIV EMORY (US) | 2025-09-10 | — | — | EP | claimed |
| CN-120037358-A | Improved combination therapy of fusion proteins of GLP-1 receptor agonists | 广州银诺医药集团股份有限公司 | 2025-05-27 | — | — | CN | claimed |
| CN-119909159-A | Use of improved fusion proteins of GLP-1 receptor agonists in the treatment of diseases | 广州银诺医药集团股份有限公司 | 2025-05-02 | — | — | CN | claimed |
| US-20250108121-A1 | METHOD FOR PRODUCING AN ANTIBODY PEPTIDE CONJUGATE | AMGEN INC. | 2025-04-03 | — | — | US | claimed |
| US-12257282-B2 | Mixtures and formulations | CAMARUS AB (SE) | 2025-03-25 | — | — | US | claimed |
| US-20240424057-A1 | METHODS AND COMPOSITION OF INHIBITING ASPROSIN MEDIATED OREXIGENESIS AND/OR GLUCOGENSIS | UNIVERSITY HOSPITALS CLEVELAND MEDICAL CENTER | 2024-12-26 | — | — | US | claimed |
| US-20220401523-A1 | FGF21 COMPOUND / GLP-1R AGONIST COMBINATIONS WITH OPTIMIZED ACTIVITY RATIO | SANOFI SA (FR) | 2022-12-22 | — | — | US | claimed |
| WO-2022258805-A1 | TREATMENT OF OBESITY AND OBESITY-RELATED DISORDERS | ANTAG THERAPEUTICS APS (DK) | 2022-12-15 | — | — | WO | claimed |
| US-11519034-B2 | Non-invasive diagnostic of non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis and/or liver fibrosis | GENFIT (FR) | 2022-12-06 | — | — | US | claimed |
| US-20220362187-A1 | COMBINATION THERAPY COMPRISING COMPOUNDS OF FORMULA (I) AND GLP-1 RECEPTOR AGONISTS | GENFIT (FR) | 2022-11-17 | — | — | US | claimed |
| EP-4074327-A1 | THERAPEUTIC AGENTS COMPRISING ELASTIN-LIKE PEPTIDES | Duke University (US) | 2022-10-19 | — | — | EP | claimed |
| US-20220315632-A1 | COMBINATION OF DIETARY PEPTIDES | DIET4LIFE APS (DK) | 2022-10-06 | — | — | US | claimed |
| CN-109789214-B | Mixtures and formulations comprising alkyl ammonium EDTA | 卡姆拉斯公司 | 2022-06-28 | — | — | CN | claimed |
| EP-4000630-A1 | ELEVATED INTRACRANIAL PRESSURE TREATMENT | Invex Therapeutics Ltd (AU) | 2022-05-25 | — | — | EP | claimed |
| EP-3236937-B1 | CONTROLLED-RELEASE FORMULATIONS | CAMURUS AB (SE) | 2022-05-04 | — | — | EP | claimed |
| EP-3952855-A1 | COMBINATION THERAPY COMPRISING COMPOUNDS OF FORMULA (I) AND GLP-1 RECEPTOR AGONISTS | Genfit (FR) | 2022-02-16 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12544371-B2 | Methods and compositions for treating acute lung injury and acute respiratory distress syndrome | ORAI1, MAVS, CASR | GLP1R 1013/4885 |
| US-20250108121-A1 | METHOD FOR PRODUCING AN ANTIBODY PEPTIDE CONJUGATE | CTSD, DNPEP, CTSZ | GLP1R 1455/4885 |
| US-20250367218-A1 | METHODS OF TREATING METABOLIC DISORDERS AND COMBINATION PRODUCTS FOR USE IN THE SAME | GLP1R, GPR119, IAPP | GLP1R 1/4885 |
| US-12257282-B2 | Mixtures and formulations | PHOSPHO1, TTPA, LIPC | GLP1R 3346/4885 |
| US-20220362187-A1 | COMBINATION THERAPY COMPRISING COMPOUNDS OF FORMULA (I) AND GLP-1 RECEPTOR AGONISTS | GLP1R, GIPR, GPR119 | GLP1R 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.